AEB3103 / Spyre Therap - LARVOL DELTA

[VIRTUAL] Therapeutic Targeting of Cystine Addiction of Renal Cell Carcinoma (KCRS-I 2020) - "In Aim 2, we will continue developing a panel of ccRCC patient-derived xenografts (PDXs) murine model that include tumors acquired from patients who have evidence of disease progression following treatment with VEGFR TKIs (sunitinib, pazopanib) as well as immune checkpoint inhibition (nivolumab)...Since cyst(e)inase is being developed by Aeglea BioTherapeutics (AEB3103) for near-future IND and clinical trials, the successful completion of the proposed projects may provide crucial rationale and information as a basis for clinical trials in the near future to target this metabolic "Achilles' heel" of RCC as a novel and crucial means of overcoming resistance. The novel therapeutic strategy proposed here could potentially offer a completely new way to treat this disease in a way that dramatically improves the health of affected military service personnel or their family members. Funding Mechanism: Idea Development Award - Established Investigator"

IO Biomarker • Clear Cell Renal Cell Carcinoma • CNS Disorders • Genito-urinary Cancer • Immune Modulation • Inflammation • Oncology • Psychiatry • Renal Cell Carcinoma • Solid Tumor • Von Hippel-Lindau Syndrome • CD34 • VHL